Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization

Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency me...

Full description

Saved in:
Bibliographic Details
Published inCancer management and research Vol. 13; pp. 4291 - 4298
Main Authors Miszczyk, Justyna, Przydacz, Mikołaj, Zembrzuski, Michał, Chłosta, Piotr L
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2021
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects
benign prostatic hyperplasia
Biomarkers
Cancer
Cancer patients
Cancer therapies
Care and treatment
Cell cycle
chromosome 1
Chromosomes
fish method
Fluorescence
Genetic aspects
Genetic research
Genital diseases
Health aspects
Hybridization
Hyperplasia
Hypertrophy
Lymphocytes
Medical research
Medicine, Experimental
Original Research
Prostate
Prostate cancer
Radiation
Radiation therapy
Radiotherapy
radiotherapy planning
X-rays
Poland
radiotherapy planning
FISH method
prostate cancer
chromosome 1
biomarkers
benign prostatic hyperplasia
Online AccessGet full text

Cover

Abstract Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method. Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure. After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+). The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.
AbstractList Purpose: Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method. Patients and Methods: Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure. Results: After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+). Conclusion: The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients. Keywords: benign prostatic hyperplasia, chromosome 1, prostate cancer, radiotherapy planning, biomarkers, FISH method
Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method.PURPOSERadiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method.Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure.PATIENTS AND METHODSWhole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure.After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+).RESULTSAfter irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+).The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.CONCLUSIONThe differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.
Purpose: Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method. Patients and Methods: Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure. Results: After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+). Conclusion: The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.
Justyna Miszczyk,1 Mikołaj Przydacz,2 Michał Zembrzuski,2 Piotr L Chłosta2 1Department of Experimental Physics of Complex Systems, The H. Niewodniczański Institute of Nuclear Physics PAN, Krakow, Poland; 2Department of Urology, Jagiellonian University Medical College, Krakow, PolandCorrespondence: Justyna MiszczykDepartment of Experimental Physics of Complex Systems, The H. Niewodniczański Institute of Nuclear Physics PAN, Radzikowskiego 152 Street, Krakow, 31-342, PolandTel +48 126628409Fax +48 126628458Email Justyna.Miszczyk@ifj.edu.plPurpose: Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method.Patients and Methods: Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure.Results: After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+).Conclusion: The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.Keywords: benign prostatic hyperplasia, chromosome 1, prostate cancer, radiotherapy planning, biomarkers, FISH method
Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the efficacy of treatment planning. This study investigated the individual susceptibility to radiation based on chromosome 1 aberration frequency measured by the FISH (fluorescence in situ hybridization) method. Whole blood samples were collected from 27 prostate cancer (PCa) patients and 32 subjects with benign prostatic hyperplasia (BPH), who were considered as a control group. Samples were irradiated with 2 Gy of x-rays, cultured, harvested, and used in the FISH procedure. After irradiation, significantly higher levels of all studied chromosome 1 aberrations (except for deletions) in the group of PCa patients were revealed. Furthermore, in the lymphocytes of cancer patients, nearly five-fold higher frequencies of acentric fragments were observed compared to the BPH group. The highest individual radiosensitivities for all estimated biomarkers were seen in PCa patient cells who reported cancer incidence in the immediate family (CIF+). The differences in chromosome 1 aberrations between PCa and BPH demonstrate that lymphocytes taken from patients with prostate cancer have higher radiosensitivity which might be related to hereditary or familiar inclinations. Therefore, this technique may find future application in searching biomarkers of the cellular radiotherapy response in prostate cancer patients.
Audience Academic
Author Chłosta, Piotr L
Przydacz, Mikołaj
Miszczyk, Justyna
Zembrzuski, Michał
Author_xml – sequence: 1
  givenname: Justyna
  orcidid: 0000-0001-7226-1750
  surname: Miszczyk
  fullname: Miszczyk, Justyna
– sequence: 2
  givenname: Mikołaj
  surname: Przydacz
  fullname: Przydacz, Mikołaj
– sequence: 3
  givenname: Michał
  surname: Zembrzuski
  fullname: Zembrzuski, Michał
– sequence: 4
  givenname: Piotr L
  orcidid: 0000-0003-2911-7627
  surname: Chłosta
  fullname: Chłosta, Piotr L
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34103984$$D View this record in MEDLINE/PubMed
BookMark eNptkkuP0zAUhSM0iHnAjjWyxIYFLfEjibNBKhXDVCpixGNtOfZ16yqxO3YyUvkz_FXcF0xHIy9s3fvdYx37XGZnzjvIstc4HxPMqg_Tr5Pv4x-kpoTVz7ILjKt6hCkhZw_O59lljKs8L2tM2YvsnDKc05qzi-zPzN1D7O1C9tY75A2aLoPvfPQdIIwmDYSwa0VkHeqXgOabbr30atND3OK3wcde9oCm0ikISDqNPoGzC3dsWYVuNmsI61ZGK9FtqoDrI2o26LodfICoII1u9aPthwQ3wWr7e3fty-y5kW2EV4f9Kvt1_fnn9GY0__ZlNp3MR6pgRT8qJCOl0TXgkiqGMWPMMCorZbTOQUqZ60Ypiqnm3NQqx0XBCaUGeJVzzRp6lc32utrLlVgH28mwEV5asSv4sBAyJCstCKYa1ZSN1qSsGKkKWWCjSGNAE1nrkietj3ut9dB0oJO7Psj2RPS04-xSLPy94LjiBadJ4N1BIPi7IX2P6Gx6pLaVDvwQBSloXZCSEZLQt4_QlR-CS0-VKEZyzGlR_acWMhmwzvh0r9qKiklZkYqUHNeJGj9BpaWhsyqlzthUPxl489DoP4fHeCWA7AGVohADGKFsv_vXpGxbgXOxzbDYZlgcMpyG3j8aOuo-if8FU-L0mQ
CitedBy_id crossref_primary_10_46879_ukroj_4_2021_48_64
Cites_doi 10.1186/s13014-020-01575-7
10.1016/j.mrrev.2003.07.003
10.4103/0975-7406.68500
10.1016/j.exger.2021.111304
10.1093/mutage/gev018
10.1016/j.eururo.2016.07.031
10.1007/s00411-009-0244-x
10.3389/fonc.2019.01563
10.1007/s004390100488
10.1016/0027-5107(95)00171-9
10.1086/301879
10.1016/j.eursup.2006.02.004
10.1016/j.eururo.2017.11.039
10.1016/j.radonc.2006.10.012
10.1016/j.mrfmmm.2007.02.023
10.1126/science.274.5291.1371
10.1007/978-3-319-20291-4_6
10.1007/978-3-319-99286-0_2
10.1093/milmed/167.suppl_1.10
10.2741/2312
10.1016/B978-0-323-35868-2.00060-8
10.1080/02841860410002824
10.1038/s41598-017-03198-7
10.3109/09553002.2013.825060
10.1016/j.ctro.2018.01.004
10.3389/fonc.2013.00113
10.1016/S0140-6736(03)12713-4
10.1038/sj.pcan.4500478
10.1016/S1569-9056(13)60184-0
10.1016/j.ijrobp.2012.09.026
10.1158/1055-9965.EPI-04-0236
10.1097/MOU.0000000000000460
ContentType Journal Article
Copyright 2021 Miszczyk et al.
COPYRIGHT 2021 Dove Medical Press Limited
2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 Miszczyk et al. 2021 Miszczyk et al.
Copyright_xml – notice: 2021 Miszczyk et al.
– notice: COPYRIGHT 2021 Dove Medical Press Limited
– notice: 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 Miszczyk et al. 2021 Miszczyk et al.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.2147/CMAR.S293249
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Miszczyk et al
EISSN 1179-1322
EndPage 4298
ExternalDocumentID oai_doaj_org_article_4cbcb6bdd2674275a51fc2bfed2a9d68
PMC8178583
A672726819
34103984
10_2147_CMAR_S293249
Genre Journal Article
GeographicLocations Poland
GeographicLocations_xml – name: Poland
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
29B
2WC
53G
5VS
7X7
8FI
8FJ
8G5
AAYXX
ABUWG
ACGFO
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HMCUK
HYE
IAO
IHR
IPNFZ
ITC
KQ8
M2O
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
NPM
PMFND
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c545t-5a426fd9e163c411444f43a7cfdd0eaaa0dbcc313d88f9c01558233fe8708d4b3
IEDL.DBID 7X7
ISSN 1179-1322
IngestDate Wed Aug 27 01:23:08 EDT 2025
Thu Aug 21 18:26:31 EDT 2025
Fri Jul 11 02:25:02 EDT 2025
Mon Jun 30 13:51:39 EDT 2025
Tue Jun 17 21:17:19 EDT 2025
Tue Jun 10 20:37:53 EDT 2025
Thu Jan 02 22:56:07 EST 2025
Tue Jul 01 02:41:28 EDT 2025
Thu Apr 24 23:01:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords radiotherapy planning
FISH method
prostate cancer
chromosome 1
biomarkers
benign prostatic hyperplasia
Language English
License http://creativecommons.org/licenses/by-nc/3.0
2021 Miszczyk et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c545t-5a426fd9e163c411444f43a7cfdd0eaaa0dbcc313d88f9c01558233fe8708d4b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2911-7627
0000-0001-7226-1750
OpenAccessLink https://www.proquest.com/docview/2542018357?pq-origsite=%requestingapplication%
PMID 34103984
PQID 2542018357
PQPubID 3933196
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_4cbcb6bdd2674275a51fc2bfed2a9d68
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8178583
proquest_miscellaneous_2539526422
proquest_journals_2542018357
gale_infotracmisc_A672726819
gale_infotracacademiconefile_A672726819
pubmed_primary_34103984
crossref_citationtrail_10_2147_CMAR_S293249
crossref_primary_10_2147_CMAR_S293249
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
– name: Macclesfield
PublicationTitle Cancer management and research
PublicationTitleAlternate Cancer Manag Res
PublicationYear 2021
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove
– name: Dove Medical Press
References Beskid (ref1) 2007; 690
Vodenkova (ref33) 2015; 30
Kaddour (ref37) 2017; 7
Gallardo (ref12) 2021; 148
(ref22) 2010
Saramäki (ref16) 2018; 12
El-Zein (ref28) 2005; 14
Mladenov (ref7) 2013; 3
Grönberg (ref8) 2003; 361
Xu (ref29) 2001; 189
Cebulska-Wasilewska (ref3) 2003; 544
(ref11) 2018
Boei (ref5) 1996; 349
Frank (ref14) 2017; 71
Smith (ref17) 1996; 274
Beaton (ref27) 2013; 85
Prasanna (ref23) 2002; 167
Chughtai (ref9) 2016; 16032
Takakusagi (ref20) 2020; 15
Berthon (ref30) 1998
Singh (ref13) 2000; 3
ref21
(ref31) 2010
Grade (ref4) 2015; 200
Distel (ref34) 2006; 81
Miszczyk (ref36) 2018; 31
Rana (ref6) 2010; 2
Robinson (ref18) 2018; 73
Podder (ref19) 2018; 1096
Beaton (ref26) 2013; 89
(ref2) 2007
Ballon-Landa (ref15) 2018; 28
Hille (ref25) 2010; 49
Fowler (ref24) 2005; 44
Mirone (ref10) 2006; 5
Wilson (ref35) 2020; 9
Miszczyk (ref32) 2012; 11
References_xml – volume: 15
  start-page: 127
  year: 2020
  ident: ref20
  publication-title: Radiat Oncol
  doi: 10.1186/s13014-020-01575-7
– volume: 544
  start-page: 289
  year: 2003
  ident: ref3
  publication-title: Mutat Res
  doi: 10.1016/j.mrrev.2003.07.003
– volume: 2
  start-page: 189
  year: 2010
  ident: ref6
  publication-title: J Pharm Bioallied Sci
  doi: 10.4103/0975-7406.68500
– volume: 148
  start-page: 111304
  year: 2021
  ident: ref12
  publication-title: Exp Gerontol
  doi: 10.1016/j.exger.2021.111304
– volume: 30
  start-page: 557
  year: 2015
  ident: ref33
  publication-title: Mutagenesis
  doi: 10.1093/mutage/gev018
– volume: 71
  start-page: 162
  year: 2017
  ident: ref14
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.07.031
– volume: 49
  start-page: 27
  year: 2010
  ident: ref25
  publication-title: Radiat Environ Biophys
  doi: 10.1007/s00411-009-0244-x
– volume: 16032
  year: 2016
  ident: ref9
  publication-title: Nature Rev
– volume: 9
  start-page: 1563
  year: 2020
  ident: ref35
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.01563
– volume: 189
  start-page: 335
  year: 2001
  ident: ref29
  publication-title: Hum Genet
  doi: 10.1007/s004390100488
– volume: 349
  start-page: 127
  year: 1996
  ident: ref5
  publication-title: Mutat Res
  doi: 10.1016/0027-5107(95)00171-9
– start-page: 1416
  year: 1998
  ident: ref30
  publication-title: Am J Hum Genet
  doi: 10.1086/301879
– volume: 5
  start-page: 410
  year: 2006
  ident: ref10
  publication-title: Eur Urol Supp
  doi: 10.1016/j.eursup.2006.02.004
– volume: 73
  start-page: 502
  year: 2018
  ident: ref18
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2017.11.039
– volume: 81
  start-page: 257
  year: 2006
  ident: ref34
  publication-title: Radiat Oncol
  doi: 10.1016/j.radonc.2006.10.012
– volume: 690
  start-page: 62
  year: 2007
  ident: ref1
  publication-title: Mutat Res
  doi: 10.1016/j.mrfmmm.2007.02.023
– volume: 274
  start-page: 1371
  year: 1996
  ident: ref17
  publication-title: Science
  doi: 10.1126/science.274.5291.1371
– volume: 200
  start-page: 115
  year: 2015
  ident: ref4
  publication-title: Recent Results Cancer Res
  doi: 10.1007/978-3-319-20291-4_6
– volume: 1096
  start-page: 31
  year: 2018
  ident: ref19
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-319-99286-0_2
– volume: 167
  start-page: 10
  year: 2002
  ident: ref23
  publication-title: Mil Med
  doi: 10.1093/milmed/167.suppl_1.10
– volume: 12
  start-page: 3287
  year: 2018
  ident: ref16
  publication-title: Front Biosci
  doi: 10.2741/2312
– volume-title: Integrative Medicine
  year: 2018
  ident: ref11
  doi: 10.1016/B978-0-323-35868-2.00060-8
– ident: ref21
– volume: 44
  start-page: 265
  year: 2005
  ident: ref24
  publication-title: Acta Oncol
  doi: 10.1080/02841860410002824
– volume-title: Rapid Diagnosis in Populations at Risk from Radiation and Chemicals
  year: 2010
  ident: ref22
– volume: 7
  start-page: 3291
  year: 2017
  ident: ref37
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-03198-7
– volume: 89
  start-page: 1087
  year: 2013
  ident: ref26
  publication-title: Int J Radiat Biol
  doi: 10.3109/09553002.2013.825060
– volume: 31
  start-page: 23
  year: 2018
  ident: ref36
  publication-title: Clin Transl Radiat Oncol
  doi: 10.1016/j.ctro.2018.01.004
– volume: 3
  start-page: 113
  year: 2013
  ident: ref7
  publication-title: Front Oncol
  doi: 10.3389/fonc.2013.00113
– volume: 361
  start-page: 859
  year: 2003
  ident: ref8
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)12713-4
– volume: 3
  start-page: 241
  year: 2000
  ident: ref13
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/sj.pcan.4500478
– volume: 11
  start-page: 126
  year: 2012
  ident: ref32
  publication-title: Eur Urol Suppl
  doi: 10.1016/S1569-9056(13)60184-0
– volume-title: Chromosomal Alterations
  year: 2007
  ident: ref2
– volume: 85
  start-page: 1346
  year: 2013
  ident: ref27
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2012.09.026
– volume: 14
  start-page: 748
  year: 2005
  ident: ref28
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-04-0236
– volume-title: Rapid Diagnosis in Populations at Risk from Radiation and Chemicals
  year: 2010
  ident: ref31
– volume: 28
  start-page: 55
  year: 2018
  ident: ref15
  publication-title: Curr Opin Urol
  doi: 10.1097/MOU.0000000000000460
SSID ssj0069134
Score 2.2016056
Snippet Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it increases the...
Purpose: Radiotherapy is one of the most common treatments for prostate cancer. Finding a useful predictor of the therapeutic outcome is crucial as it...
Justyna Miszczyk,1 Mikołaj Przydacz,2 Michał Zembrzuski,2 Piotr L Chłosta2 1Department of Experimental Physics of Complex Systems, The H. Niewodniczański...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 4291
SubjectTerms benign prostatic hyperplasia
Biomarkers
Cancer
Cancer patients
Cancer therapies
Care and treatment
Cell cycle
chromosome 1
Chromosomes
fish method
Fluorescence
Genetic aspects
Genetic research
Genital diseases
Health aspects
Hybridization
Hyperplasia
Hypertrophy
Lymphocytes
Medical research
Medicine, Experimental
Original Research
Prostate
Prostate cancer
Radiation
Radiation therapy
Radiotherapy
radiotherapy planning
X-rays
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gRUYCcUChie0kznG7YrVCLKqASr1Fjh80UutUye5hfw1_tTN5rBIhxIVrPInizNjzTTzzDSHvrBMy0iILNVcmFJli2MjdhTwx4KytTiODgeLmW7q-EF8uk8tJqy_MCevpgfsPdyp0qcu0NIalEMVliUpip1nprGEqN2lX5gs-bwym-j04Hc-TwdxCjLf6lHfsyXO63Cy-f_oBXo4hf-bEGXWc_X_uzBPXNE-bnPih1SPycACQdNG_-GNyz_on5P5mOCJ_Sn5PmDNqT2tHkf_2pm7rG0tjuiht0yu9pZWnAP_o1z1otNZ7AJ0ofo51IIBA6RINoqHKG3pmffXLj0OVpmsIX5vbrgSTnvfUrC0t93R1vaubjiFKW3x-W213IIxlYUPB5zNysfr8c7kOhy4MoQZ0tQ0TBU7cmdwCctMCwichnOAq086YyCqlIlNqzWNupHS5RgwmGefOwk4gjSj5c3Lka29fEqqzyKQR14mRmbDMqkRl4B4lhFXc5jIOyMdRHYUeKMqxU8Z1AaEKKq9A5RWD8gLy_iB921Nz_EXuDDV7kEFC7e4CmFkxmFnxLzMLyAe0iwKXPbySVkP1AkwMCbSKRXeinQK-CsjxTBKWq54Pj5ZVDNtFW0CUDkAMwHAWkLeHYbwTU-C8rXcow_ME4CtjAXnRG-JhSgBFIp5LEZBsZqKzOc9HfHXVkYnLOJOJ5K_-x0d6TR4wTPnp_lAdk6Nts7MngNm25Ztued4BcKJB8A
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-G3vTomg-CA92yRt0geRvcVlEVcOdeHeSpqkZ2GvPdtdcP8a_1Vn-rFsOfW1mZZmZ6bzm83Mbwh55XKhAiOkb7i2vpCa4SD33OeRhWDtTBxYTBQXX-L5Uny6iC4OyDBttP8Bm7-mdjhPalmvTn_93H4Ah3-PZcyhkO-mi8nX028QtyCVuEVuQ0yS6KILsTtPiPF8uSt7v3HHKCC1vP03v8574WlcOrkXi2b3yb0eRNJJp_UH5MCVD8mdRX9M_oj83mPPqEpa5RQ5cK-qprpyNKSTzNWd4htalBQgIP28Ba1WZgvAE8XPsRcEUCidolHUVJeWnrmyuCyHpcLQOaSw9XXbhknPO3rWhmZbOlttqrpliTIOn98U6w0IY2tY3_T5mCxnH79P534_icE3gLDWfqQhkOc2cYDejIAUSohccC1Nbm3gtNaBzYzhIbdK5YlBHKYY57mDr4GyIuNPyGFZle4ZoUYGNg64iaySwjGnIy0hRCpIrbhLVOiRt4M6UtPTlOO0jFUK6QoqL0Xlpb3yPPJ6J33d0XP8Q-4MNbuTQVLt9kJVX6a9j6bCZCaLM2tZLAWTkY7C3LAsd5bpxMbKI2_QLlI0Rnglo_sOBtgYkmilk_ZUOwaM5ZGTkSS4rBkvD5aVDhafQqYOYAwAsfTIy90y3ollcKWrNijDkwggLGMeedoZ4m5LAEcCnijhETky0dGexytl8aMlFFehVJHiR_9_rWNyl2FBT_v_0wk5XNcb9xwQ2Tp70TrbH05gOD0
  priority: 102
  providerName: Scholars Portal
Title Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization
URI https://www.ncbi.nlm.nih.gov/pubmed/34103984
https://www.proquest.com/docview/2542018357
https://www.proquest.com/docview/2539526422
https://pubmed.ncbi.nlm.nih.gov/PMC8178583
https://doaj.org/article/4cbcb6bdd2674275a51fc2bfed2a9d68
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nj9MwELVgV0JcEN8ElspIIA4obGI7sXNCbbVLheiqWlipt8ixnaXSblLS9tBfw19lJnFLIwSXHOppFXfGnjf2zBtC3rpSqMgIGRqubSikZtjIvQx5YsFZO5NGFgPF6UU6uRJf5sncH7itfFrlbk9sN2pbGzwjP4VABnwV4AX5afkzxK5ReLvqW2jcJcdIXYYpXXK-D7hSvFXukt2xG8_peDq8_PgN_BtD5swDN9Sy9f-9Jx84pX7C5IEHOn9IHnjoSIedrh-RO656TO5N_eX4E_LrgDOjrmhdUmS-va1X9a2jMR0WrunUvaKLigLwo1-3oMvabAFuovgMK0AAe9IxmkJDdWXpyFWL62o3tDB0AoFrs2yLL-msI2Vd0WJLz282ddNyQxmHvw__2waEsSDMl3o-JVfnZ9_Hk9D3XwgN4Kp1mGhw36XNHGA2IyBwEqIUXEtTWhs5rXVkC2N4zK1SZWYQfSnGeelgD1BWFPwZOarqyr0g1MjIphE3iVVSOOZ0oiU4RgUBFXeZigPyYaeO3HhycuyRcZNDkILKy1F5uVdeQN7tpZcdKcc_5Eao2b0MUmm3H9TNde5XZi5MYYq0sJalUjCZ6CQuDStKZ5nObKoC8h7tIscFD69ktK9bgIkhdVY-bO-yU0BWATnpScJCNf3hnWXlfqNY5X_MOiBv9sP4TUx-q1y9QRmeJQBcGQvI884Q91MCEBLxTImAyJ6J9ubcH6kWP1oacRVLlSj-8v-v9YrcZ5jG0546nZCjdbNxrwGHrYtBu9gG5Hh0djG7HLSnGfD8PI_hORXqN3CROlk
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVAIuiDeGAotExQG5dXbX9vqAUBIapTSJotJKvZn17rpEau3gJEL5NfwDfiMzfoRECG69ZieWV_PtzDfeeRDy1qZCelqErubKuCJUDAe5py73DThrqwPPYKA4GgeDc_H5wr_YIb-aWhhMq2xsYmmoTa7xG_khBDLgq4AvhB9n312cGoW3q80IjQoWJ3b1A0K2-YfjT6Dffcb6R2e9gVtPFXA1sIWF6ytwSqmJLDARLSAcECIVXIU6NcazSinPJFrzNjdSppFGTiEZ56kFZEsjEg7PvUV2BYdQpkV2u0fjyWlj-wO8x67S63H-z2Fv1Dk9-AIelWGvzg3HV84H-NsLbLjB7RTNDZ_Xv0_u1WSVdip0PSA7NntIbo_q6_hH5OdGl448o3lKsdfudT7Pry1t005iiwpgczrNKFBNOlwBenK9AoKL4hOsOQG2S3sIvoKqzNCuzaaXWbM01XQAoXIxK8s96aRqAzunyYr2r5Z5UXaj0hafD5pagjCWoNXFpY_J-Y3o5glpZXlmnxGqQ88EHte-kaGwzCpfheCKJYRw3Eay7ZD3jTpiXbdDx6kcVzGERai8GJUX18pzyP5aela1AfmHXBc1u5bB5t3lD3lxGde2IBY60UmQGMOCULDQV3471SxJrWEqMoF0yDvERYwmBl5Jq7pSAjaGzbriTnl7HgCXc8jeliSYBr293CArrk3TPP5zkBzyZr2M_8R0u8zmS5ThkQ9UmTGHPK2AuN4S0B6PR1I4JNyC6Naet1ey6beycblsh9KX_Pn_X-s1uTM4Gw3j4fH45AW5yzCJqPzmtUdai2JpXwILXCSv6qNHydebPu2_AbYUdKw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkCZeEN8EBhiJiQcUmtpO7Dwg1HVUHVunCpjUt-DYzqi0JaUfQv1r-D_467jLR2mE4G2v9TWKdee738V3vyPklcuECoyQvuHa-kJqhoPcM5-HFoK1M1FgMVEcnUXDc_FxEk52yK-mFwbLKhufWDpqWxj8Rt6BRAZiFeAF2cnqsojx0eD97LuPE6TwprUZp1GZyIlb_4D0bfHu-Ah0fcDY4MOX_tCvJwz4BpDD0g81BKjMxg5QiRGQGgiRCa6lyawNnNY6sKkxvMutUllsEF8oxnnmwMqVFSmH594gNyUPu3jG5GST7EV4o10V2uMkoE5_1Pv09jPEVoasnVshsJwU8Hc82AqI7WLNreg3uENu17CV9io7u0t2XH6P7I3qi_n75OcWX0eR0yKjyLp7VSyKK0e7tJe6eWVqCzrNKYBOeroGOyrMGqAuio-x-wRwL-2jGc6pzi09dPn0Im-WpoYOIWmez8rGTzquCGEXNF3TweWqmJe8VMbh80FPKxDGZrS6zfQBOb8WzTwku3mRu8eEGhnYKOAmtEoKx5wOtYSgrCCZ4y5WXY-8adSRmJoYHedzXCaQIKHyElReUivPIwcb6VlFCPIPuUPU7EYGabzLH4r5RVJ7hUSY1KRRai2LpGAy1GE3MyzNnGU6tpHyyGu0iwSdDbyS0XXPBGwMabuSXnmPHgGq88h-SxKchGkvN5aV1E5qkfw5Uh55uVnGf2LhXe6KFcrwOATQzJhHHlWGuNkSAKCAx0p4RLZMtLXn9ko-_VZSmKuuVKHiT_7_Wi_IHpzx5PT47OQpucWwmqj8-LVPdpfzlXsGcHCZPi_PHSVfr_ug_wadPnd8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Investigation+of+Chromosome+1+Aberrations+in+the+Lymphocytes+of+Prostate+Cancer+and+Benign+Prostatic+Hyperplasia+Patients+by+Fluorescence+in+situ+Hybridization&rft.jtitle=Cancer+management+and+research&rft.au=Miszczyk%2C+Justyna&rft.au=Przydacz%2C+Miko%C5%82aj&rft.au=Zembrzuski%2C+Micha%C5%82&rft.au=Ch%C5%82osta%2C+Piotr+L&rft.date=2021-01-01&rft.pub=Taylor+%26+Francis+Ltd&rft.eissn=1179-1322&rft.volume=13&rft.spage=4291&rft_id=info:doi/10.2147%2FCMAR.S293249&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1322&client=summon